JP2016535779A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016535779A5 JP2016535779A5 JP2016552430A JP2016552430A JP2016535779A5 JP 2016535779 A5 JP2016535779 A5 JP 2016535779A5 JP 2016552430 A JP2016552430 A JP 2016552430A JP 2016552430 A JP2016552430 A JP 2016552430A JP 2016535779 A5 JP2016535779 A5 JP 2016535779A5
- Authority
- JP
- Japan
- Prior art keywords
- crystalline form
- pharmaceutical composition
- oxy
- disease
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 238000000634 powder X-ray diffraction Methods 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000007771 core particle Substances 0.000 claims 3
- -1 7-azaspiro [3.5] nonan-7-yl Chemical group 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000003607 modifier Substances 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 229920000428 triblock copolymer Polymers 0.000 claims 2
- TWCHPQYRRRXRDD-UHFFFAOYSA-N 4-[4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxyquinazolin-7-yl]oxy-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCC(=O)N(CC1)CCC21COC2 TWCHPQYRRRXRDD-UHFFFAOYSA-N 0.000 claims 1
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- PCDHSSHKDZYLLI-UHFFFAOYSA-N butan-1-one Chemical compound CCC[C]=O PCDHSSHKDZYLLI-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 201000000159 corneal neovascularization Diseases 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 239000002736 nonionic surfactant Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 208000004644 retinal vein occlusion Diseases 0.000 claims 1
- 239000002002 slurry Substances 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 238000001238 wet grinding Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361898741P | 2013-11-01 | 2013-11-01 | |
| US61/898,741 | 2013-11-01 | ||
| US14/184,886 | 2014-02-20 | ||
| US14/184,886 US9353123B2 (en) | 2013-02-20 | 2014-02-20 | Therapeutic compounds and uses thereof |
| PCT/US2014/063630 WO2015066584A1 (en) | 2013-11-01 | 2014-11-03 | Crystalline forms of therapeutic compounds and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018199872A Division JP2019038824A (ja) | 2013-11-01 | 2018-10-24 | 治療用化合物の結晶形態及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016535779A JP2016535779A (ja) | 2016-11-17 |
| JP2016535779A5 true JP2016535779A5 (enrdf_load_stackoverflow) | 2017-03-16 |
| JP6426195B2 JP6426195B2 (ja) | 2018-11-21 |
Family
ID=53005242
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016552430A Expired - Fee Related JP6426195B2 (ja) | 2013-11-01 | 2014-11-03 | 治療用化合物の結晶形態及びその使用 |
| JP2018199872A Pending JP2019038824A (ja) | 2013-11-01 | 2018-10-24 | 治療用化合物の結晶形態及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018199872A Pending JP2019038824A (ja) | 2013-11-01 | 2018-10-24 | 治療用化合物の結晶形態及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP3062795A4 (enrdf_load_stackoverflow) |
| JP (2) | JP6426195B2 (enrdf_load_stackoverflow) |
| AU (1) | AU2014341966B2 (enrdf_load_stackoverflow) |
| CA (2) | CA2928665A1 (enrdf_load_stackoverflow) |
| WO (1) | WO2015066584A1 (enrdf_load_stackoverflow) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014341966B2 (en) * | 2013-11-01 | 2017-08-17 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3666254B1 (en) | 2017-08-11 | 2024-12-04 | Amorepacific Corporation | Pharmaceutical composition containing (r)-n-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide |
| KR102518632B1 (ko) | 2018-04-18 | 2023-04-06 | (주)아모레퍼시픽 | (r)-n-[1-(3,5-다이플루오로-4-메테인설폰일아미노-페닐)-에틸]-3-(2-프로필-6-트라이플루오로메틸-피리딘-3-일)-아크릴아마이드를 함유하는 약학 조성물 |
| WO2020179837A1 (en) | 2019-03-04 | 2020-09-10 | Ricoh Company, Ltd. | Cooperation processing apparatus and method |
| GB201915447D0 (en) * | 2019-10-24 | 2019-12-11 | Johnson Matthey Plc | Polymorphs of avapritinib and methods of preparing the polymorphs |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7074800B1 (en) * | 1999-02-10 | 2006-07-11 | Astrazeneca Ab | Quinazoline derivatives as angiogenesis inhibitors |
| RU2362775C1 (ru) * | 2002-02-01 | 2009-07-27 | Астразенека Аб | Хиназолиновые соединения |
| CL2004000409A1 (es) * | 2003-03-03 | 2005-01-07 | Vertex Pharma | Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu |
| GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
| GB0330002D0 (en) * | 2003-12-24 | 2004-01-28 | Astrazeneca Ab | Quinazoline derivatives |
| WO2006040526A1 (en) * | 2004-10-12 | 2006-04-20 | Astrazeneca Ab | Quinazoline derivatives for use against cancer |
| MX368903B (es) * | 2013-02-20 | 2019-10-21 | Kala Pharmaceuticals Inc | Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas. |
| AU2014341966B2 (en) * | 2013-11-01 | 2017-08-17 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
-
2014
- 2014-11-03 AU AU2014341966A patent/AU2014341966B2/en not_active Ceased
- 2014-11-03 EP EP14857110.2A patent/EP3062795A4/en not_active Withdrawn
- 2014-11-03 WO PCT/US2014/063630 patent/WO2015066584A1/en active Application Filing
- 2014-11-03 JP JP2016552430A patent/JP6426195B2/ja not_active Expired - Fee Related
- 2014-11-03 CA CA2928665A patent/CA2928665A1/en not_active Abandoned
- 2014-11-03 CA CA3109285A patent/CA3109285A1/en not_active Abandoned
-
2018
- 2018-10-24 JP JP2018199872A patent/JP2019038824A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016535779A5 (enrdf_load_stackoverflow) | ||
| JP2014512356A5 (enrdf_load_stackoverflow) | ||
| JP2013523846A5 (enrdf_load_stackoverflow) | ||
| JP2014509659A5 (enrdf_load_stackoverflow) | ||
| JP2014512354A5 (enrdf_load_stackoverflow) | ||
| HRP20100559T1 (hr) | Liječenje neovaskularnih poremećaja oka, poput makularne degeneracije, angioidnih strija, uveitisa i edema makule | |
| JP2016027060A5 (enrdf_load_stackoverflow) | ||
| WO2007084765A3 (en) | Injectable combination therapy for eye disorders | |
| MX347544B (es) | Antagonista de acido lisofostatidico 1 (lpa1) policiclico y usos del mismo. | |
| EP2508207A1 (en) | Nanoparticles loaded with chemotherapeutic antitumoral Drug | |
| JP2016510326A5 (enrdf_load_stackoverflow) | ||
| JP2014506582A5 (enrdf_load_stackoverflow) | ||
| WO2007075720A3 (en) | Topical mecamylamine formulations for ocular administration and uses thereof | |
| JP2011509301A5 (enrdf_load_stackoverflow) | ||
| JP6749962B2 (ja) | 網脈絡膜障害の抑制剤 | |
| JP2018527287A5 (enrdf_load_stackoverflow) | ||
| JP2015503579A5 (enrdf_load_stackoverflow) | ||
| WO2011159100A2 (ko) | 항암 활성을 나타내는 약제학적 조성물 | |
| WO2008092072A3 (en) | Modulators of the metabotropic glutamate receptor subtype 5 and uses thereof | |
| JP2019038824A (ja) | 治療用化合物の結晶形態及びその使用 | |
| CN106999492B (zh) | 具有抗癌活性的6-氧代-1,6-二氢-哒嗪衍生物与喹唑啉衍生物的组合 | |
| RU2017112930A (ru) | Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза | |
| WO2008048675A3 (en) | Treatment for age-related macular degeneration and other diseases of the eye | |
| JP2017525758A5 (enrdf_load_stackoverflow) | ||
| EP4494705A3 (en) | Non-peptide oxytocin receptor agonists |